News Home

Should Biotechnology Stock Theravance Biopharma Inc (TBPH) Be in Your Portfolio Monday?

Monday, October 03, 2022 03:34 PM | InvestorsObserver Analysts
Should Biotechnology Stock Theravance Biopharma Inc (TBPH) Be in Your Portfolio Monday?

The 67 rating InvestorsObserver gives to Theravance Biopharma Inc (TBPH) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 72 percent of stocks in the Biotechnology industry, TBPH’s 67 overall rating means the stock scores better than 67 percent of all stocks.

Overall Score - 67
TBPH has an Overall Score of 67. Find out what this means to you and get the rest of the rankings on TBPH!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Theravance Biopharma Inc Stock Today?

Theravance Biopharma Inc (TBPH) stock has fallen -0.84% while the S&P 500 has risen 2.93% as of 3:34 PM on Monday, Oct 3. TBPH is down -$0.09 from the previous closing price of $10.14 on volume of 511,160 shares. Over the past year the S&P 500 has fallen -14.18% while TBPH has risen 35.58%. TBPH lost -$1.36 per share the over the last 12 months. Click Here to get the full Stock Report for Theravance Biopharma Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App